The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of continued imatinib (IM) in pts with detectable BCR-ABL after ≥ 2 years on study on deep molecular responses (MR): 36-month update from ENESTcmr.
Nelson Spector
Research Funding - Novartis
Nelma Cristina D. Clementino
No relevant relationships to disclose
Pedro Enrique Dorlhiac-Llacer
Research Funding - Novartis
Brian Leber
Honoraria - Novartis
Timothy P. Hughes
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis
Francisco Cervantes
Consultant or Advisory Role - ADP; Gilead Sciences; Novartis
Honoraria - Bristol-Myers Squibb; Novartis
Anthony P. Schwarer
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Donna L. Forrest
No relevant relationships to disclose
Suzanne Kamel-Reid
Honoraria - Novartis
Research Funding - Novartis
Israel Bendit
No relevant relationships to disclose
Sandip Acharya
Employment or Leadership Position - Novartis
LaTonya Collins
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Darshan Dalal
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Jeffrey H. Lipton
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva